PUT/ELI LILLY & CO/500/0.1/17.01.25 | Real-time BOERSE MUENCHEN 11:25:40 11/07/2024 BST | ||
| 0.18 EUR | +24.14% |
|
| Current month | -18.99% | ||
| 1 month | -44.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 11/07/24 | 0.18 | +24.14% |
| 10/07/24 | 0.145 | -18.08% |
| 09/07/24 | 0.177 | +1.14% |
| 08/07/24 | 0.175 | -14.22% |
| 05/07/24 | 0.204 | -2.86% |
Real-time BOERSE MUENCHEN
Last update July 11, 2024 at 11:25 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Goldman Sachs |
| WKN | GG5ZLA |
| ISIN | DE000GG5ZLA8 |
| Date issued | 27/03/2024 |
| Strike | 500 $ |
| Maturity | 17/01/2025 (191 Days) |
| Parity | 10 : 1 |
| Emission price | 0.63 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.87 € |
|---|---|
| Lowest since issue | 0.141 € |
| Spread | 0.15 € |
| Spread % | 45.45% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
877.2
USD
Spread / Average Target
-6.66%
- Stock Market
- Warrants
- Warrant
